Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1
Keywords: Dog; Monoclonal antibody; PD-1; PD-L1;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
PD-1 /PD-L1 checkpoint in hematological malignancies
Keywords: PD-1; PD-L1; PD-1/PD-L1 checkpoint; Lymphoproliferative disorders; Immunotherapy;
Dendritic cells conditioned by activin A-induced regulatory T cells exhibit enhanced tolerogenic properties and protect against experimental asthma
Keywords: Activin-A; allergic asthma; regulatory T cells; tolerogenic dendritic cells; immune regulation; Act-A-Treg; Activin-A-induced regulatory T; alum; Aluminum hydroxide; BAL; Bronchoalveolar lavage; BM-DCs; Bone marrow-derived dendritic cell; cDC; Convent
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC
Keywords: Lung cancer; NSCLC; Checkpoint inhibitors; Biomarkers; PD-L1;
Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3
Keywords: Fraxinellone; PD-L1; STAT3; HIF-1α; Proliferation; Angiogenesis;
Checkpoint inhibitors as treatment for malignant gliomas: “A long way to the top”
Keywords: Checkpoint inhibitors; Immunotherapy; Malignant gliomas; Glioblastoma; PD-1; PD-L1;
Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells
Keywords: HDAC; histone deacetylase; HOXA5; homeobox A5; PD-1; programmed death 1; PD-L1; programmed death-ligand 1; shRNA; short hairpin RNA; STAT3; signal transducer and activator of transcription 3;
MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy
Keywords: EGFR TKI; MET mutation; Pathway activation; PD-L1; Predictive parameter;
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab
Keywords: Pembrolizumab; Anti-PD-1 antibody; PD-L1; Non-small cell lung cancer;
PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective
Keywords: Neuroblastoma; PD-L1; Inflammation; Non-coding RNAs; Immuno-therapy;
PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation
Keywords: BLI; bioluminescence imaging; BSA; bovine serum albumin; CTL; cytotoxic T lymphocytes; CRISPR/Cas; Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR associated nucleases; DEGs; differently expressed genes; DMEM; Dulbecco's modified Eagle's
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Keywords: Atezolizumab; PD-L1; Checkpoint inhibitor; Non-small cell lung cancer; Cancer immunotherapy;
Human CD40 ligand-expressing type 3 innate lymphoid cells induce IL-10-producing immature transitional regulatory B cells
Keywords: Type 3 innate lymphoid cells; immature transitional regulatory B cells; regulatory B cells; tonsils; allergy; asthma; IL-10; immunoregulation; immune tolerance; APC; Allophycocyanin; APRIL; A proliferation-inducing ligand; BAFF; B cell-activating factor
Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups
Keywords: BRD4; BI2536; Indoline; WPF binders; c-Myc; PD-L1; BCPs; Bromodomain-containing proteins; BET; bromodomain and extra-terminal; BRD4-BD1; first bromodomain of BRD4; CREB; cyclic-AMP response element binding protein; FA; fluorescence anisotropy; FBDD; fragm
DNA mismatch repair in cancer
Keywords: 5-FU; 5-fluorouracil; bMMRD; Biallelic mismatch repair deficiency; CD28; cluster of differentiation 28; CIN; Chromosomal instable; CR; complete response; CRC; colorectal cancer; CTL; cytotoxic T-lymphocytes; CTLA-4; cytotoxic T lymphocyte antigen-4; DFS;
TGFβ pathway inhibition in the treatment of non-small cell lung cancer
Keywords: ALK; Anaplastic leukemia kinase; CAF; Cancer-associated fibroblast; EGFR; Epidermal growth factor receptor; EMT; Epithelial-to-mesenchymal transition; MSC; Mesenchymal stem cell; NK Cell; Natural killer cell; NSCLC; Non-small cell lung cancer; OS; Overall
Review articlePD-L1 IHC in NSCLC with a global and methodological perspective
Keywords: PD-L1; Immunohistochemistry; Validation; Lung cancer; Pathology; Review;
PD-L1 expression in HNPCC-associated colorectal cancer
Keywords: Colorectal cancer; HNPCC; Lynch syndrome; PD-L1; Mismatch repair enzymes;
MYC expression correlates with PD-L1 expression in non-small cell lung cancer
Keywords: Immune checkpoint inhibitors; Myc; Non-small cell lung cancer (NSCLC); PD-L1;
Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies
Keywords: PD-1; PD-L1; haemangioma;
Proteogenomic analysis of NCC-S1M, a gastric cancer stem cell-like cell line that responds to anti-PD-1
Keywords: PD-L1; Ccne1; Il1rl1; Gastric; Cancer; CSC; cancer stem cell; CGH; comparative genomic hybridization; LC; liquid chromatography; MS; mass spectrometry; NGE; normal gastric epithelium; TGF; transforming growth factor; TMA; tumor tissue microarray;
Short communicationPoly I:C primes the suppressive function of human palatine tonsil-derived MSCs against Th17 differentiation by increasing PD-L1 expression
Keywords: Tonsil-derived MSCs; PD-L1; Th17; Poly I:C;
Hypoxia and HIF pathway in cancer and the placenta
Keywords: Oxygen; Hypoxia-inducible factor; Placenta; Trophoblast; Cancer; CCRCC; clear cell renal cell carcinoma; FasL; Fas ligand; FIH; factor inhibiting HIF; FLT1; fms-related tyrosine kinase 1; HIF; hypoxia-inducible factor; HLA; human leukocyte antigen; MHC; m
Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma
Keywords: HIFs; hypoxia-inducing factors; RCC; renal cell carcinoma; VHL; von Hippel-Lindau; CTLs; cytotoxic T lymphocytes; mRCC; metastatic renal cell carcinoma; IL; interleukin; IFN; interferon; PD-1; programmed cell death-1; PD-L1; PD-ligand-1; CTLA-4; cytotoxic
Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors
Keywords: High grade serous ovarian cancer; Treatment naïve; PD-L1; Tumor-associated macrophages; BRCA;
A novel mimovirus encoding ChgA10-19 peptide with PD-L1 induces T cell tolerance and ameliorates the severity of diabetes
Keywords: Mimovirus; ChgA10-19; PD-L1; T cell tolerance; Diabetes;
PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis
Keywords: Juvenile recurrent respiratory papillomatosis (JRRP); PD-L1; CD8+;
Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India
Keywords: PD-L1; Programmed death ligand 1; Lung cancer; Non-small cell lung carcinoma; Oncogenic drivers; Immune cells;
CD40 agonist converting CTL exhaustion via the activation of the mTORC1 pathway enhances PD-1 antagonist action in rescuing exhausted CTLs in chronic infection
Keywords: CD40 agonist; PD-1 antagonist; Chronic infection; CTL exhaustion; mTORC1 pathway; CTL; cytotoxic T lymphocytes; DT; diphtheria toxin; DC; dendritic cell; LCMV; lymphocytic choriomeningitis virus; OVA; ovalbumin; PD-1; programmed cell death protein 1; PD-L
PD-L1 expression in neuroendocrine tumors of the lung
Keywords: Neuroendocrine; Carcinoid; LCNEC; Small cell lung cancer; PD-1; PD-L1; Immunohistochemistry; Clone E1L3N;
Programmed Death - Ligand 1 Expression Distinguishes Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features
Keywords: Thyroid cancer; Follicular variant; PTC; NIFTP; PD-L1; Invasion; Protein biomarker;
Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples
Keywords: Immunomodulation; Laboratory correlates; NSCLC; PD-L1; Pembrolizumab;
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment1
Keywords: PD-1; PD-L1; Bladder cancer; BCG failure; Immunotherapy; Biomarker;
PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma
Keywords: Skin cancer; squamous cell carcinoma; immunohistochemistry; PD-L1; PD-1; tumour biomarkers; tumour microenvironment; tumour heterogeneity; disease-free survival;
Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients
Keywords: ALP; Alkaline Phosphatase; ALT; alanine transaminase; AST; aspartate aminotransferase; BSA; Bovine Serum Albumin; CRP; C-Reactive Protein; CV; Coefficient of Variation; ECOG; Eastern Cooperative Oncology Group; EMA; European Medicines Agency; FDA; Food an
Identification of repaglinide as a therapeutic drug for glioblastoma multiforme
Keywords: Repaglinide; Glioma; Bioinformatics; Drug repositioning; Cancer therapy; Brain tumor; CMap; connectivity map; DE genes; differentially expressed genes; DMEM; Dulbecco's modified Eagle's medium; DMSO; dimethyl sulfoxide; FBS; fetal bovine serum; GBM; gliob
Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages
Keywords: Oral squamous cell carcinoma; PD-L1; Macrophages;
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)
Keywords: Thymoma; Thymic carcinoma; Gene mutations; c-KIT; PD-L1;
PD-1 and PD-L1 expression in bone and soft tissue sarcomas
Keywords: Bone sarcoma; soft tissue sarcoma; PD-1; PD-L1;
In this issuePD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus
Keywords: Thymic neoplasms; Thymus; PD-L1; PD-1; Cd; CD8;
Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma
Keywords: Immunotherapeutics; Kidney; PD-L1; Renal pelvis; Ureter; Urothelial carcinoma;
Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates
Keywords: Nivolumab; Opdivo; PET; Zirconium-89; PD-1; PD-L1; BMS-936558;
Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis
Keywords: CI; confidence interval; HR; hazard ratio; OR; odds ratio; PD-1; programmed death-1; PD-L1; programmed death-ligand 1; p-stage; pathological stage; SI; smoking index; B7-H3; Immune checkpoint; Immunotherapy; Lung cancer; Smoking; Prognostic interaction;
Radiosensitivity gene signatureA radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset
Keywords: Breast cancer; Radiosensitivity gene signature; TCGA; PD-L1; CD274;
Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer
Keywords: High grade serous ovarian cancer; PD-L1; Tumor-infiltrating lymphocytes; Prognosis;
Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer
Keywords: PD-L1; PD-1 ligand; NSCLC; non-small cell lung cancer; SNPs; single nucleotide polymorphisms; PD-1; programed cell death-1; CTLA-4; cytotoxic T lymphocyte-associated antigen 4; OS; overall survival; IHC; immunohistochemistry; HRs; hazard ratios; HWE; Hard
Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions
Keywords: CIS; carcinoma in situ; H&E; hematoxylin and eosin; PD-1; programmed death 1; PD-L1; programmed death ligand 1; SIN; squamous intraepithelial neoplasia; TAM; tumor-associated macrophage; TIL; tumor-infiltrating lymphocyte; Oral cancer; Oral leukoplakia; P
Construction of high level prokaryotic expression and purification system of PD-L1 extracellular domain by using Escherichia coli host cell machinery
Keywords: PCR; polymerase chain reaction; ECD; extracellular domain; TM; trans-membrane; CD; cytoplasmic domain; PD-L1; programmed cell death ligand 1; PDL1-ECD; programmed cell death ligand 1- extracellular domain; ERS; enzyme restriction sites; Ori; origin of rep
Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis
Keywords: PD-L1; Non-small cell lung cancer; Driven genes; Meta-analysis;
Mini-reviewPD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges
Keywords: PD1; PD-L1; NSCLC; Efficacy; Challenges; PD-1; programmed death-1; PD-L1; programmed death ligand-1; NSCLC; Non-small cell lung cancer; ORR; overall response rate; DOR; duration of response; OS; overall survival; PFS; progression free survival; AE; advers